BFC Planning’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$176K Buy
761
+118
+18% +$29.2K 0.01% 982
2026
Q2
$155K Buy
643
+599
+1,361% +$131K 0.01% 1036
2026
Q1
$8.32K Hold
44
– – ﹤0.01% 2121
2025
Q4
$7.48K Sell
44
-7
-14% -$1.07K ﹤0.01% 2189
2025
Q3
$6.72K Buy
51
+3
+6% +$360 ﹤0.01% 2085
2025
Q2
$5.09K Sell
48
-36
-43% -$3.91K ﹤0.01% 2044
2025
Q1
$10.4K Buy
84
+40
+91% +$5.22K ﹤0.01% 1750
2024
Q4
$5.42K Hold
44
– – ﹤0.01% 1992
2024
Q3
$4.9K Buy
+44
New +$4.82K ﹤0.01% 2018

Other funds holding JAZZ

BFC Planning's JAZZ Position: Q3 2026 in Review

BFC Planning increased its Jazz Pharmaceuticals (JAZZ) stake by 18% in Q3 2026, buying an estimated $29.2K and bringing the position to 761 shares worth $176K. The position accounts for 0.01% of the portfolio, ranked #982.

BFC Planning first reported a position in JAZZ in Q3 2024 and has held it in 9 quarters since. 547 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • BFC Planning held 761 shares of Jazz Pharmaceuticals worth $176K as of Q3 2026.
  • BFC Planning bought 118 Jazz Pharmaceuticals shares in Q3 2026, an estimated $29.2K.
  • Jazz Pharmaceuticals made up 0.01% of BFC Planning's portfolio in Q3 2026, its #982 holding.
  • BFC Planning first reported a position in Jazz Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • 547 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.